Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06875960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06875960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 4
Overall status
Recruiting
Start date
February 24, 2026
Completion date
January 31, 2028
Enrollment
35 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

discoid and/or subacute cutaneous lupus erythematosus (dle/scle), systemic lupus erythematosus (sle)